ZA201204940B - Co-crystals of a triazolo [4,5-d] pyrimidine platelet aggregation inhibitor - Google Patents
Co-crystals of a triazolo [4,5-d] pyrimidine platelet aggregation inhibitorInfo
- Publication number
- ZA201204940B ZA201204940B ZA2012/04940A ZA201204940A ZA201204940B ZA 201204940 B ZA201204940 B ZA 201204940B ZA 2012/04940 A ZA2012/04940 A ZA 2012/04940A ZA 201204940 A ZA201204940 A ZA 201204940A ZA 201204940 B ZA201204940 B ZA 201204940B
- Authority
- ZA
- South Africa
- Prior art keywords
- triazolo
- pyrimidine
- crystals
- platelet aggregation
- aggregation inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26630709P | 2009-12-03 | 2009-12-03 | |
PCT/GB2010/002222 WO2011067571A1 (fr) | 2009-12-03 | 2010-12-03 | Co-cristaux d'un inhibiteur d'agrégation plaquettaire à base de triazolo [4,5-d] pyrimidine |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA201204940B true ZA201204940B (en) | 2013-03-27 |
Family
ID=43535876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2012/04940A ZA201204940B (en) | 2009-12-03 | 2012-07-02 | Co-crystals of a triazolo [4,5-d] pyrimidine platelet aggregation inhibitor |
Country Status (12)
Country | Link |
---|---|
US (1) | US8883802B2 (fr) |
EP (1) | EP2507242A1 (fr) |
JP (1) | JP2013512886A (fr) |
KR (1) | KR20120123659A (fr) |
CN (2) | CN104230936A (fr) |
AU (1) | AU2010326361A1 (fr) |
BR (1) | BR112012013365A2 (fr) |
CA (1) | CA2781182A1 (fr) |
MX (1) | MX2012006375A (fr) |
RU (1) | RU2012126029A (fr) |
WO (1) | WO2011067571A1 (fr) |
ZA (1) | ZA201204940B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013014035A (es) * | 2011-06-01 | 2014-01-23 | Astrazeneca Ab | Nuevo co-cristal ticagrelor. |
WO2013150495A2 (fr) | 2012-04-05 | 2013-10-10 | Dr. Reddy's Laboratories Limited | Préparation de ticagrelor |
WO2013186726A2 (fr) * | 2012-06-15 | 2013-12-19 | Basf Se | Cristaux à plusieurs composants comprenant du dasatinib et des agents de formation de cocristaux choisis |
EA024825B8 (ru) * | 2012-06-29 | 2016-12-30 | Зентива, К.С. | Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение |
CA2877541C (fr) | 2012-07-04 | 2020-06-30 | Lek Pharmaceuticals D.D. | Produits d'addition de ticagrelor et de sels metalliques divalents |
CZ2012705A3 (cs) | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
MX2015013059A (es) * | 2013-03-15 | 2016-08-05 | Bionomics Ltd | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. |
WO2014170026A1 (fr) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Ticagrelor amorphe stabilisé |
EP2813216A1 (fr) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Ticagrelor amorphe stabilisé |
CN104341423B (zh) * | 2013-08-02 | 2017-03-01 | 上海京新生物医药有限公司 | 替格瑞洛的一水合物及其制备方法与在制药中的应用 |
CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
CN103601726B (zh) * | 2013-12-02 | 2016-09-28 | 浙江大学 | 两种替格瑞洛药物共晶及其制备方法 |
WO2015183801A1 (fr) | 2014-05-27 | 2015-12-03 | R. J. Reynolds Tobacco Company | Sels, co-cristaux, et complexes de co-cristaux de sels de nicotine |
US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
WO2016116942A1 (fr) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine |
CN108495563B (zh) | 2015-11-25 | 2022-04-26 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体配合物 |
CA3009610C (fr) | 2015-12-24 | 2024-02-13 | Takeda Pharmaceutical Company Limited | Cocristal de (s)(1-((1-acryloylpyrrolidine-3-yl)oxy)isoquinoline-3-yl)-1h-1,2,4-triazole-5(4h)-one, methode de production et composition pharmaceutique comprenant le cocristal |
US10905691B2 (en) | 2016-09-09 | 2021-02-02 | Université de Liège | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection |
EP3292867B1 (fr) * | 2016-09-09 | 2019-05-15 | Université de Liège | Dérivés triazolo(4,5-d)pyrimidines pour la prevention et le traitement d'infections bacteriennes |
WO2019049049A1 (fr) | 2017-09-05 | 2019-03-14 | R. J. Reynolds Tobacco Company | Sels, co-cristaux, et complexes de co-cristaux de sels de nicotine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
-
2010
- 2010-12-03 BR BR112012013365A patent/BR112012013365A2/pt not_active IP Right Cessation
- 2010-12-03 CN CN201410302272.7A patent/CN104230936A/zh active Pending
- 2010-12-03 WO PCT/GB2010/002222 patent/WO2011067571A1/fr active Application Filing
- 2010-12-03 US US13/513,482 patent/US8883802B2/en not_active Expired - Fee Related
- 2010-12-03 MX MX2012006375A patent/MX2012006375A/es not_active Application Discontinuation
- 2010-12-03 AU AU2010326361A patent/AU2010326361A1/en not_active Abandoned
- 2010-12-03 JP JP2012541573A patent/JP2013512886A/ja active Pending
- 2010-12-03 KR KR1020127017184A patent/KR20120123659A/ko not_active Application Discontinuation
- 2010-12-03 CN CN2010800630504A patent/CN102770434A/zh active Pending
- 2010-12-03 EP EP10803467A patent/EP2507242A1/fr not_active Withdrawn
- 2010-12-03 CA CA2781182A patent/CA2781182A1/fr not_active Abandoned
- 2010-12-03 RU RU2012126029/04A patent/RU2012126029A/ru not_active Application Discontinuation
-
2012
- 2012-07-02 ZA ZA2012/04940A patent/ZA201204940B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2012006375A (es) | 2013-03-21 |
CA2781182A1 (fr) | 2011-06-09 |
CN104230936A (zh) | 2014-12-24 |
CN102770434A (zh) | 2012-11-07 |
JP2013512886A (ja) | 2013-04-18 |
AU2010326361A1 (en) | 2012-06-07 |
KR20120123659A (ko) | 2012-11-09 |
BR112012013365A2 (pt) | 2016-03-01 |
US20130040970A1 (en) | 2013-02-14 |
US8883802B2 (en) | 2014-11-11 |
EP2507242A1 (fr) | 2012-10-10 |
WO2011067571A1 (fr) | 2011-06-09 |
RU2012126029A (ru) | 2014-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201204940B (en) | Co-crystals of a triazolo [4,5-d] pyrimidine platelet aggregation inhibitor | |
IL266285B (en) | Methods for the production of thiano [d – 3,2] pyrimidine compounds | |
HK1192248A1 (en) | Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors [43-d] | |
IL257410A (en) | Pyrazolo [1, 5 – a ] pyrimidines as antiviral agents | |
ZA201202718B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
IL228590A0 (en) | History of pyrrolo[3,2-d] pyrimidine as inhibitors of tropomyosin-linked kinases | |
ZA201208544B (en) | 5,7-substitute-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases | |
EP2608669A4 (fr) | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor | |
AP3709A (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
AP3751A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
EP2751112A4 (fr) | Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci | |
EP2525659A4 (fr) | Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor | |
IL227526A0 (en) | Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors | |
EP2739627A4 (fr) | Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2 | |
EP2661437A4 (fr) | Dérivés de 2,4-diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine comme inhibiteurs de fak/pyk2 | |
IL215315A0 (en) | Solid state forms of sitagliptin salts | |
ZA201403441B (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid | |
IL224450B (en) | Crystalline forms of pyrimido[6,1-a] isoquinolin-4-one compounds | |
EP2536279A4 (fr) | Formes cristallines de 4-{[9-chloro-7-(2-fluoro-6-méthoxyphényl)-5h-pyrimido[5,4-d][2]benzazépin-2yl]amino}-2-méthoxybenzoate de sodium | |
ZA201406323B (en) | Triazolo[4,5-d]pyrimidine derivatives | |
EP2523552A4 (fr) | Pyrazolo[1,5-a]pyrimidines comme inhibiteurs de mark | |
ZA201202097B (en) | Crystalline forms of substituted pyrazolopyrimidines | |
HK1211850A1 (en) | Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy [43-d] | |
PT2729475E (pt) | Derivados do ácido carboxílico com um anel de oxazolo[4,5-d pirimidina | |
AU2011355362B2 (en) | 5-([1,2,3]Triazole-4-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives |